PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neurobiol Aging. Author manuscript; available in PMC 2013 April 1.
Published in final edited form as:
PMCID: PMC3236809
NIHMSID: NIHMS316799

Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons

Jessica B.S. Langbaum, PhD,a,h,1 Kewei Chen, PhD,a,b,h Lenore J. Launer, PhD,c Adam S. Fleisher, MD,a,d,h Wendy Lee, MS,a,h Xiaofen Liu, MS,a,h Hillary D. Protas, PhD,a,h Stephanie A. Reeder, BA,a,h Daniel Bandy, MS,a,h Meixiang Yu, PhD,a,2 Richard J. Caselli, MD,e,h and Eric M. Reiman, MDa,f,g,h

Abstract

Epidemiological studies suggest that elevated blood pressure (BP) in mid-life is associated with increased risk of Alzheimer’s disease (AD) in late-life. In this preliminary study, we investigated the extent to which BP measurements are related to positron emission tomography (PET) measurements of fibrillar amyloid-beta burden using Pittsburgh Compound-B (PiB) and fluorodeoxyglucose (FDG) PET measures of cerebral metabolic rate for glucose metabolism (CMRgl) in cognitively normal, late-middle-aged to older adult apolipoprotein E (APOE) ε4 homozygotes, heterozygotes and non-carriers. PiB PET results revealed that systolic BP (SBP) and pulse pressure (PP) were each positively correlated with cerebral-to-cerebellar PiB distribution volume ratio (DVR) in frontal, temporal and posterior-cingulate/precuneus regions, whereas no significant positive correlations were found between PiB DVRs and diastolic BP (DBP). FDG PET results revealed significant inverse correlations between each of the BP measures and lower CMRgl in frontal and temporal brain regions. These preliminary findings provide additional evidence that higher BP, likely a reflection of arterial stiffness, during late-mid-life may be associated with increased risk of presymptomatic AD.

Keywords: APOE, blood pressure, arterial stiffness, brain imaging, PET, Alzheimer’s disease, amyloid, PiB, Pittsburgh Compound-B

1. Introduction

Epidemiological studies have raised the possibility that cardiovascular risk factors such as elevated blood pressure (BP) in mid-life are associated with increased risk for Alzheimer’s disease (AD) in late-life (Freitag et al., 2006; Launer et al., 2000; Skoog et al., 1996). However, cross-sectional and longitudinal studies in older adults have not confirmed this association (Morris et al., 2000; Morris et al., 2001; Petitti et al., 2005; Qiu et al., 2004; Verghese et al., 2003), instead suggesting that in late-life, lower BP is associated with increased risk of AD, with the decrease occurring perhaps as a secondary phenomenon in AD due to damage to brain regions important to BP regulation (Burke et al., 1994; Guo et al., 1996; Guo et al., 2001b). As a complement to traditional epidemiological studies we have proposed using brain imaging measurements as a quantitative presymptomatic endophenotype of AD, a feature more closely related to disease predisposition than the clinical syndrome itself (Reiman et al., 2001; Reiman et al., 2005). Utilizing established imaging measures that distinguish people with no copies, one copy and two copies of the apolipoprotein E (APOE) ε4 allele, the best established genetic risk factor for late-onset AD (Corder et al., 1993), we can evaluate the relationship between BP, amyloid pathology, brain function, and this well-established genetic risk factor in the predisposition to AD.

Examining fluorodeoxyglucose (FDG) positron emission tomography (PET) images from cognitively normal, late-middle-aged persons, we previously reported that compared to non-carriers (NC), APOE ε4 homozygotes (HM) and heterozygotes (HT) have significantly lower measures of the cerebral metabolic rate for glucose metabolism (CMRgl) in brain regions preferentially affected by AD (Reiman et al., 1996), and in fact, this reduction is correlated with gene dose (the number of ε4 alleles in a person’s APOE genotype) (Reiman et al., 2005). Examining the relationship between cerebral hypometabolism, APOE ε4, and serum total cholesterol, another cardiovascular risk factor suggested to increase the risk of AD, we previously reported that increasing cholesterol levels are associated with lower CMRgl bilaterally AD-related brain regions and in additional frontal regions preferentially affected by normal aging, and these reductions are greater in APOE ε4 carriers compared to NC (Reiman et al., 2010a). Using another brain imaging measurement of preclinical AD, Pittsburgh Compound-B (PiB) PET (Klunk et al., 2004), which assesses fibrillar amyloid-beta (Aβ) in vivo, we previously reported that cognitively normal late-middle-age APOE ε4 carriers have greater fibrillar Aβ burden compared to NC, and in fact, the fibrillar Aβ measurements are correlated with APOE ε4 gene dose (Reiman et al., 2009).

In the present study, we used our proposed neuroimaging endophenotypes to test the hypothesis that elevated BP measurements of systolic BP (SBP), diastolic BP (DBP) and peripheral pulse pressure (PP) in cognitively normal, late middle-aged persons are associated with increased PiB burden and lower CMRgl in brain regions known to be preferentially affected by AD and normal aging and to examine the impact of APOE ε4 on these relationships.

2. Methods

2.1. Study population

Cognitively normal volunteers 47 to 68 years of age were enrolled into a longitudinal cohort study (Reiman et al., 1996, 2005). Participants provided informed consent, agreeing not to be given any information about their APOE genotype and were studied under guidelines approved by the human subjects committees at Banner Good Samaritan Medical Center and the Mayo Clinic. Venous blood samples were drawn and APOE ε4 genotypes characterized as previously described (Crook et al., 1994; Reiman et al., 1996). Originally, one APOE ε4 HT (with the ε3/ε4 genotype) and two ε4 NC were matched to a different ε4 HM for their gender, age (within 3 years), and educational level (within 2 years). All participants denied having an impairment in memory or other cognitive skills, had scores of at least 28 on the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and less than 10 on the Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960), did not satisfy criteria for a current psychiatric disorder using a structured psychiatric interview, and had a normal neurological exam. Study participants have been assessed every two years using a medical examination, including collecting information on history of hypertension and use of blood pressure lowering medications, using clinical ratings, neuropsychological tests, volumetric MRI (to rule out gross clinical abnormalities and for analysis purposes) and FDG PET (Reiman et al., 1996; Reiman et al., 2001). Beginning in December 2007, study participants underwent PiB PET scans and BP measurements were acquired as part of their study visit. At the time of their PET scans, all returning subjects remained cognitively normal. For the current cross-sectional report, we analyzed the available BP, FDG PET and PiB PET data from our returning APOE ε4 HM, HT, and NC enrolled in our longitudinal cohort study. PiB and BP data were available for 32 participants whereas FDG PET data were available for 26 participants. Ten participants underwent both FDG PET and PiB PET as part of this study.

2.2 Measurement of blood pressure

Mean SBP and DBP was computed from three supine measurements using an automated cuff (GE Dinamap PRO 400) by a trained PET technician during the PET study visit as follows: 1) just prior to IV insertion, 2) during the transmission scan just prior to injection, and 3) immediately after the scan. PP was calculated as the difference between mean SPB and DBP. Participants were classified as hypertensive if their mean SBP or DBP measurements met JCN7 criteria for hypertension (SBP ≥140 and/or DBP ≥90 mm/Hg) (Chobanian et al., 2003).

2.3 Brain Imaging

Volumetric T1-weighted MRI, PiB PET and FDG PET were performed as previously described (Reiman et al., 1996; Reiman et al., 2001; Reiman et al., 2009). Briefly, PiB PET was performed using the HR+ scanner (Siemens, Knoxville, TN) in the three-dimensional mode, a transmission scan, the intravenous injection of 15 mCi of 11C-PiB, and a 90-min dynamic sequence of emission scans. Each person’s PiB PET image was reconstructed using a filter back-projection method, correction for radiation scatter and attention, and a Hanning filter. The data were converted to cerebral-to-cerebellar PiB DVR, a measure of fibrillar Aβ burden, using images from the 40-to-90 min emission frames, an automatically labeled cerebellar reference region, and the Logan method. The Logan method was used to generate PiB DVR images in order to characterize and compare PiB DVR on a voxel-by-voxel basis (Reiman et al., 2009).

FDG PET was also performed using the HR+ scanner in the three-dimensional mode, a transmission scan, the intravenous injection of 5–8 mCi of [18F] fluorodeoxyglucose, and a 60-minute dynamic sequence of emission scans as the participants, who had fasted for at least 4 hours, lay quietly with eyes closed in a darkened room. The reconstructed images consisted of 63 horizontal slices with a center-to-center slice separation of 2.46 mm, an axial field of view of 15.5 cm, an in-plane resolution of 4.2–5.1 mm full width at half-maximum (FWHM), and an axial resolution of 4.6–6.0 mm FWHM. Voxel-based analyses were performed using the PET images (counts relative to the whole brain uptake) acquired during the last 30 minutes.

2.4 Data analysis

For the PiB PET analyses, SPM5 (Wellcome Department of Cognitive Neurology, London, U.K.), and spatial information from the 3.5-to-10 min emission frames were used to automatically linearly and non-linearly deform the PiB distribution volume ratio (DVR) image according to the coordinates of a standard brain atlas (Talairach and Tournoux, 1988), smooth the images to 12 mm full width-at-half-maximum and generate statistical parametric maps of the association between BP measurements and PiB DVR on a voxel-by voxel basis. Following the primary correlation analysis, several voxel-by-voxel post-hoc analyses were conducted, including 1) controlling for self-reported use of antihypertensive medication for treatment of hypertension and/or BP measurements that met JCN7 criteria for hypertension as described in Section 2.2 (using analysis of covariance), 2) examining the Pearson correlations between BP measures and PiB DVRs in the APOE ε4 carrier and NC groups, 3) examining the interactions between BP measures and PiB DVRs, and 4) a Monte-Carlo simulation (MCS) to examine the probability of observing the results of the present study. Specifically, MCS was used to examine the probability of observing at least N voxels in the hypothesized direction of the correlation (inverse correlation for PP and SBP with PiB DVR, positive correlation for DBP and PiB DVR) and at most n voxels in the opposite direction (where N[dbl greater-than sign]n). The assumption is that, if the hypothesis is not true (or the Null hypothesis of no correlation is true), then the N and n should not be significantly different (or observing the correlations in both directions should be random with equal chance). For each of the 1000 simulations, J (referring to the number of subjects in the study) Gaussian distributed random maps (within the whole brain mask used in the analysis) were generated, being independent to each other. Each map was then smoothed with the same FWHM used in the real analysis (also accounting for the reconstructed smoothness). The real PP, SBP or DBP were used in the simulation to compute the correlation with the random maps and to generate the corresponding t-score map for statistical significance. The number of voxels in the hypothesized direction of the correlation was recorded (referred to as dirN) as well as the number in the opposite direction (referred to as oppN). Over the 1000 simulations, we counted the number of occurrences (referred to as No), that dirN>=N and oppN<n and then estimated the probability as Prob=No/1000.

For the FDG PET analyses, an automated algorithm (SPM5) was used to deform each person’s FDG PET image linearly and non-linearly into the coordinates of a standard brain atlas, normalize the data for the variation in absolute whole-brain measurements using proportionate scaling, smooth the images using a three-dimensional Gaussian filter to a spatial resolution of 12 mm full-width-at-half-maximum, and generate statistical parametric maps of the Pearson correlations between BP measurements and lower regional CMRgl (p < 0.005, uncorrected for multiple comparisons). The statistical maps were superimposed onto a map of CMRgl reductions in previously studied probable AD patients and a spatially standardized, volume-rendered MRI (Alexander et al., 2002).

All non-imaging data, including demographics, neuropsychological scores, and blood pressure were examined using one-way analysis of variance (ANOVA) and chi-square tests with Stata 11.0 (StataCorp, College Station, TX).

3. Results

Participant characteristics, clinical ratings, neuropsychological scores, and BP measurements are shown in Table 1. Among PET PiB study participants, the APOE ε4 HM, HT, and NC groups did not differ in terms of their demographic features, BP measurements, use of antihypertensive medications, or cognitive functioning, with the exception that the HM had slightly higher mean HAM-D scores (p = 0.03), though all were within normal limits. Among FDG PET study participants, the APOE ε4 groups did not differ in regards to these same characteristics, with the exception that the HT were slightly older (p =0.04). Comparing PET PiB study participants to FDG PET study participants (excluding the 10 participants who underwent both PET PiB and FDG PET), the two imaging groups did not differ, with the exception that the PET PiB participants were slightly older (p = 0.02) (data not displayed). Participants’ MRIs were read by the radiologist and were found to be free of gross clinically significant abnormalities.

Table 1
Participant characteristics, clinical ratings, neuropsychological scores and blood pressure measurements

3.1 PET PiB results

Statistical parametric maps of the relationship between BP measurements and PiB DVR measurements of fibrillar Aβ are shown in Figure 1 with the location and magnitude of the most significant correlations in Table 2. SBP was positively correlated with PiB DVRs bilaterally in the posterior cingulate-precuneus, frontal, temporal and parietal regions. In comparison, no significant positive correlations were observed between DBP and PiB DVRs, and in fact, upon inspection, DBP was found to be inversely correlated with PiB DVRs (lower DBP with higher PiB DVRs) bilaterally in the posterior cingulate-precuneus, frontal, temporal and parietal regions (p < 0.05, uncorrected for multiple comparisons, data not shown). Based on these observations and given that PP is the absolute difference between SBP and DBP, we then examined PP separately. Higher PP was positively associated with PiB DVRs in the precuneus, frontal and parietal regions (p < 0.05, uncorrected for multiple comparisons). The results from the post-hoc interaction analyses revealed that in fact, PP is associated with an increase in PiB DVRs compared to either SBP or DBP whereas no significant interactions were found in the opposite direction. Results from the post-hoc analyses examining the association between PP and PiB DVRs which controlled for participants’ use of antihypertensive medication and/or meeting criteria for JCN7 hypertension were nearly identical to the primary Pearson correlation analysis. Similarly, post-hoc analyses controlling for APOE ε4 did not significantly alter the primary results.

Figure 1
Statistical brain maps showing correlations between higher Pittsburgh Compound-B PET measurements of fibrillar amyloid-β burden and (A) higher systolic blood pressure, (B) higher pulse pressure (p < 0.05, uncorrected for multiple comparisons) ...
Table 2
Location and magnitude of maximally significant relationships between higher blood pressure measurements and fibrillar Aβ burden

Results from the MCS revealed that, over the 1000 simulations, for each of the PP, SBP, and DBP the probability for observing the results in the hypothesized direction of correlation (that is, positive correlation between SBP or PP and PiB DVR; inverse correlation between DBP and PiB DVR) was in fact greater than the probability of observing voxels in the opposite direction (PP p = 0.005; SBP p < 0.001; DBP p < 0.001). These results indicate that the BP and PiB DVR findings observed are in fact robust.

3.2 FDG PET results

Statistical parametric maps of the inverse association between BP measurements and lower CMRgl are displayed in Figure 2 and the location and magnitude of the most significant correlations between higher SBP, DBP and PP with lower CMRgl are shown in Table 3. Higher SBP, DBP, and PP levels were each correlated with lower CMRgl in frontal and temporal brain regions (p < 0.005, uncorrected for multiple comparisons). Correlations in the opposite direction (lower BP levels with higher CMRgl) were observed bilaterally in the cerebellum and medial temporal brain regions for SBP and PP, and in the left inferior temporal brain region for DBP (p < 0.005, uncorrected for multiple comparisons) (data not displayed).

Figure 2
Statistical brain maps showing the correlations between lower CMRgl and (A) higher systolic blood pressure, (B) higher diastolic blood pressure, and (C) higher pulse pressure and (p < 0.005, uncorrected for multiple comparisons) are shown in dark ...
Table 3
Location and magnitude of the most significant correlations between higher blood pressure measurements and lower regional-to-whole brain CMRgl

4. Discussion

This study in cognitively normal, late middle-aged to older adults demonstrates a positive association between measures of BP and fibrillar Aβ burden and an inverse association between the same BP measures and CMRgl. These brain imaging findings were not solely attributable to APOE ε4 status, self-reported use of antihypertensive medications or meeting criteria for hypertension. Indeed, these findings are in agreement with those from our larger cohort indicating that the presence of cerebrovascular risk factors is associated with preclinical memory decline in APOE ε4 homozygotes (Caselli et al., 2011). Taken together, these results suggest that incremental increases in BP measures, here likely reflecting increased arterial stiffness, may be associated with increased risk of presymptomatic AD.

The findings from the present study support those from previous neuroimaging and neuropathology studies on the negative impact of elevated BP and increased arterial stiffness on brain function and structure. Findings from MRI studies suggest that hypertension exacerbates brain aging (Raz and Rodrigue, 2006), is associated with greater ventricular volume (Salerno et al., 1992; Strassburger et al., 1997) and reduced overall brain volume (Wiseman et al., 2004), while increases in SBP are associated with reduced grey matter volume (Gianaros et al., 2006). Moreover, untreated hypertension in mid-life is associated with hippocampal atrophy in late-life (Korf et al., 2004). Findings from FDG PET studies suggest that even those with medically-controlled hypertension have reduced cerebral glucose metabolism in brain regions related to AD and aging (Beason-Held et al., 2007; Salerno et al., 1995). Autopsy studies have reported that elevated BP is associated with the hallmark neuropathological markers of AD, including increased neurofibrillary tangles, amyloid plaques, and brain atrophy compared to age-matched normotensive individuals (Petrovitch et al., 2000; Sparks et al., 1995; Sparks et al., 1996).

The pathophysiological mechanism by which elevated BP or increased arterial stiffness influences the development of AD has not been elucidated. Moreover, which BP component is most predictive of presymptomatic AD and clinical AD is uncertain, as findings from our study suggest that PP, a measure of arterial stiffness, may be the most sensitive, though other studies suggest SBP may be most informative (Freitag et al., 2006). It is plausible that PP, which is a pulsatile component that is an indicator of large artery stiffness, is a better predictor of presymptomatic AD, whereas SBP is a better predictor in older adults closer to the median age of onset of dementia symptoms. Results from recent molecular studies suggest that circulatory defects, such as those caused by stiffening of the vasculature system, may result in failure of clearance of Aβ from the brain (Bell et al., 2009). Another possibility is that white matter lesions due to increases in BP may reduce cerebral blood flow thus contributing to AD or operate in an additive fashion with AD neuropathology to worsen cognition function resulting in dementia (a “critical threshold” hypothesis) (Petrovitch et al., 2000). Alternatively, increasing BP levels or arterial stiffness in mid-life could have a direct effect on the development of neuropathological features of AD or brain atrophy (Petrovitch et al., 2000), potentially due to the reduction in the blood-brain barrier caused by hypertension, resulting in amyloid deposition (Gentile et al., 2009). On the other hand, increases in BP may alter the responsiveness of the cerebrovasculature to neuronal activation, resulting in reduced cognitive functioning (Jennings et al., 1998).

Several observational studies have suggested that use of antihypertensive medications may be associated with a lower prevalence and incidence of dementia and AD and preserved cognitive function (Guo et al., 1999; Haag et al., 2009; Hajjar et al., 2005; Hanon et al., 2008; in’t Veld et al., 2001; Khachaturian et al., 2006). However, the findings from randomized clinical trials have been mixed, with some trials finding a protective effect against cognitive decline or incident dementia (Forette et al., 1998; Forette et al., 2002), with others finding no beneficial effects (Diener et al., 2008; Lithell et al., 2003). The inconsistent findings may be due to several factors, including duration of treatment (Haag et al., 2009; Peila et al., 2006) and age in which treatment was started (Haag et al., 2009), particularly because findings from some studies suggest that treatment may be most effective in reducing incident AD in those younger than 75 years of age. Moreover, there is some evidence that only APOE ε4 carriers experience the protective effect of antihypertensive medications (Guo et al., 2001a; Hestad and Engedal, 2006), potentially due to an interaction between cerebrovascular disease and ε4 (Caselli et al., in press). Inconsistent findings may also be due to type of medication, as there is some evidence to suggest that only angiotensin receptor blockers and angiotensin converting enzyme (ACE) inhibitors, and not other blood pressure-lowering medications, are associated with a reduced risk of AD (Li et al., 2010). Findings from the study of AD-model transgenic mice (Wang et al., 2007) and expired brain donors (Hoffman et al., 2009) suggest that antihypertensive treatments may protect against AD neuropathology, potentially by reducing vascular and arterial stiffness, thereby increasing blood flow to the brain and aiding in the removal of amyloid (Bell et al., 2009). In vitro studies suggest that ACE may play a role in the metabolism of Aβ, and while this is somewhat paradoxical in light of clinical studies which report a beneficial effect of ACE inhibitors on development of AD, it is possible that the beneficial effect is due to their ability to reduce the renin angiotensin system (Takeda et al., 2008).

Though the findings in the present study were obtained in a cohort of cognitively normal, predominately normotensive individuals, demonstrating that even small incremental increases in BP reflecting arterial stiffness may be associated with presymptomatic AD, there are some potential limitations. For instance, the sample size was small and requires validation in a larger cohort, which may help clarify the FDG PET results and lack of positive correlation between DBP and PiB burden. In addition, the PET PiB DVR analyses used a lenient statistical threshold, though the findings were restricted to brain regions that are relevant to AD, reducing the false positive rate, and were supported by the MCS findings. Moreover, in contrast to previous epidemiological studies (Haan et al., 1999; Peila et al., 2001; Qiu et al., 2003), as well as our own clinical study (Caselli et al., 2011), the results from the present study did not indicate an APOE ε4 effect. Also, participants in our study have a reported family history of probable AD and are generally in good health, thereby potentially reducing the generalizability of our findings to other populations. That said, our findings, which should be viewed as hypothesis generating and are likely applicable to individuals who would enroll in a presymptomatic AD trial (Reiman et al. 2011; Reiman et al., 2010b). Future studies will examine the additive effect of having multiple cerebrovascular risk factors on these neuroimaging measures of presymptomatic AD, the impact of white matter hypterintensity burden on the association between BP and our neuroimaging measures of presymptomatic AD, the longitudinal relationship between BP and our presymptomatic endophenotypes, and whether other, more sensitive measures of arterial stiffness, such as central PP, are better suited to detect an effect compared to standard brachial BP measures. In addition, future studies will examine the relationship between these brain imaging measures and volumetric MRI, by utilizing a multimodal multivariate network analysis approach (Chen et al., 2009) to characterize the linkage between the patterns of information from the same subject’s complementary MRI, FDG PET and PET PiB images to fully characterize the relationship between BP and these brain imaging measurements.

Acknowledgments

This work was supported by the National Institute of Mental Health (R01MH57899 to EMR), the National Institute on Aging (R01AG031581 and P30AG19610 to EMR), the state of Arizona (EMR, RJC, KC), and contributions from the Banner Alzheimer’s Foundation and Mayo Clinic Foundation. We thank Cole Reschke, Jennifer Keppler and Anita Prouty for their assistance.

Footnotes

Disclosure Statement: The authors who took part in this project have no actual or potential conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Reference List

  • Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry. 2002;159:738–745. [PubMed]
  • Beason-Held LL, Moghekar A, Zonderman AB, Kraut MA, Resnick SM. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke. 2007;38:1766–1773. [PubMed]
  • Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van NW, Miano JM, Zlokovic BV. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143–153. [PMC free article] [PubMed]
  • Burke WJ, Coronado PG, Schmitt CA, Gillespie KM, Chung HD. Blood pressure regulation in Alzheimer’s disease. Journal of the Autonomic Nervous System. 1994;48:65–71. [PubMed]
  • Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM. Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozgyotes [PMC free article] [PubMed]
  • Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM. Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozgyotes. Neurology. 2011;76:1078–1084. [PMC free article] [PubMed]
  • Chen K, Reiman EM, Huan Z, Caselli RJ, Bandy D, Ayutyanont N, Alexander GE. Linking functional and structural brain images with multivariate network analyses: A novel application of the partial least square method. Neuroimage. 2009;47:602–610. [PMC free article] [PubMed]
  • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. [PubMed]
  • Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. [PubMed]
  • Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994;53:125–127. [PubMed]
  • Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De KJ, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875–884. [PMC free article] [PubMed]
  • Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. [PubMed]
  • Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. The Prevention of Dementia With Antihypertensive Treatment: New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study. Archives of Internal Medicine. 2002;162:2046–2052. [PubMed]
  • Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347–1351. [PubMed]
  • Freitag MH, Peila R, Masaki K, Petrovitch H, Ross GW, White LR, Launer LJ. Midlife Pulse Pressure and Incidence of Dementia: The Honolulu-Asia Aging Study. Stroke. 2006;37:33–37. [PubMed]
  • Gentile MT, Poulet R, Pardo AD, Cifelli G, Maffei A, Vecchione C, Passarelli F, Landolfi A, Carullo P, Lembo G. β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiology of Aging. 2009;30:222–228. [PubMed]
  • Gianaros PJ, Greer PJ, Ryan CM, Jennings JR. Higher blood pressure predicts lower regional grey matter volume: Consequences on short-term information processing. Neuroimage. 2006;31:754–765. [PMC free article] [PubMed]
  • Guo Z, Fratiglioni L, Viitanen M, Lannfelt L, Basun H, Fastbom J, Winblad B. Apolipoprotein E Genotypes and the Incidence of Alzheimer’s Disease among Persons Aged 75 Years and Older: Variation by Use of Antihypertensive Medication? American Journal of Epidemiology. 2001a;153:225–231. [PubMed]
  • Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and Progression of Dementia in a Community Population Aged 75 Years and Older: Relationship of Antihypertensive Medication Use. Archives of Neurology. 1999;56:991–996. [PubMed]
  • Guo Z, Qiu C, Viitanen M, Fastbom J, Winblad B, Fratiglioni L. Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. J Alzheimers Dis. 2001b;3:585–591. [PubMed]
  • Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996;312:805–808. [PMC free article] [PubMed]
  • Haag MDM, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. Duration of antihypertensive drug use and risk of dementia. A prospective cohort study. Neurology. 2009;72:1727–1734. [PubMed]
  • Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282:40–46. [PubMed]
  • Hajjar I, Catoe H, Sixta S, Boland R, Johnson D, Hirth V, Wieland D, Eleazer P. Cross-Sectional and Longitudinal Association Between Antihypertensive Medications and Cognitive Impairment in an Elderly Population. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60:67–73. [PubMed]
  • Hamilton M. A rating scale for depression. J neurol neurosurg psychiatry. 1960:56–62. [PMC free article] [PubMed]
  • Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, Sedefdjian A, Sevenier F, Shlyakhto EV, Pathak A. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008;26:1642–1650. [PubMed]
  • Hestad KA, Engedal K. Antihypertensive medication is associated with less cognitive impairment in the very old with apolipoprotein-E epsilon4 allele. Drugs Aging. 2006;23:723–731. [PubMed]
  • Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72:1720–1726. [PMC free article] [PubMed]
  • in’t Veld BA, Ruitenberg A, Hofman A, Stricker BHC, Breteler MMB. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiology of Aging. 2001;22:407–412. [PubMed]
  • Jennings JR, Muldoon MF, Ryan CM, Mintun MA, Meltzer CC, Townsend DW, Sutton-Tyrrell K, Shapiro AP, Manuck SB. Cerebral Blood Flow in Hypertensive Patients: An Initial Report of Reduced and Compensatory Blood Flow Responses During Performance of Two Cognitive Tasks. Hypertension. 1998;31:1216–1222. [PubMed]
  • Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JCS. Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study. Archives of Neurology. 2006;63:686–692. [PubMed]
  • Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319. [PubMed]
  • Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension. 2004;44:29–34. [PubMed]
  • Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49–55. [PubMed]
  • Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465. [PMC free article] [PubMed]
  • Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension. 2003;21:875–886. [PubMed]
  • Morris MC, Scherr PA, Hebert LE, Bennett DA, Wilson RS, Glynn RJ, Evans DA. The Cross-sectional Association Between Blood Pressure and Alzheimer’s Disease in a Biracial Community Population of Older Persons. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2000;55:M130–M136. [PubMed]
  • Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of Incident Alzheimer Disease and Blood Pressure Measured From 13 Years Before to 2 Years After Diagnosis in a Large Community Study. Archives of Neurology. 2001;58:1640–1646. [PubMed]
  • Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37:1165–1170. [PubMed]
  • Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke. 2001;32:2882–2889. [PubMed]
  • Petitti DB, Crooks VC, Buckwalter JG, Chiu V. Blood Pressure Levels Before Dementia. Archives of Neurology. 2005;62:112–116. [PubMed]
  • Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21:57–62. [PubMed]
  • Qiu C, von SE, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke. 2004;35:1810–1815. [PubMed]
  • Qiu C, Winblad B, Fastbom J, Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology. 2003;61:655–660. [PubMed]
  • Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev. 2006;30:730–748. [PubMed]
  • Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci USA. 2001;98:3334–3339. [PubMed]
  • Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer’s disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med. 1996;334:752–758. [PubMed]
  • Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA. 2005;102:8299–8302. [PubMed]
  • Reiman EM, Chen K, Langbaum JB, Lee W, Reschke C, Bandy D, Alexander GE, Caselli RJ. Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer’s disease and normal aging. Neuroimage. 2010a;49:169–176. [PMC free article] [PubMed]
  • Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JBS, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-β burden in cognitively normal people at three levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA. 2009;106:6820–6825. [PubMed]
  • Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. In: Ashford JW, editor. Handbook of Imaging the Alzheimer Brain. IOS Press; Amsterdam: [PMC free article] [PubMed]
  • Reiman EM, Langbaum JBS, Tariot PN. Alzheimer’s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers in Medicine. 2010b;4:3–14. [PMC free article] [PubMed]
  • Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Disease. 2011;25(Suppl 3):293–301. [PMC free article] [PubMed]
  • Salerno JA, Grady C, Mentis M, Gonzalez-Aviles A, Wagner E, Schapiro MB, Rapoport SI. Brain metabolic function in older men with chronic essential hypertension. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 1995;50:M147–M154. [PubMed]
  • Salerno JA, Murphy DG, Horwitz B, DeCarli C, Haxby JV, Rapoport SI, Schapiro MB. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study. Hypertension. 1992;20:340–348. [PubMed]
  • Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141–1145. [PubMed]
  • Sparks DL, Scheff SW, Liu H, Landers T, Danner F, Coyne CM, Hunsaker JC. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer’s disease patients. J Neurol Sci. 1996;138:97–104. [PubMed]
  • Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. Journal of the Neurological Sciences. 1995;131:162–169. [PubMed]
  • Strassburger TL, Lee HC, Daly EM, Szczepanik J, Krasuski JS, Mentis MJ, Salerno JA, DeCarli C, Schapiro MB, Alexander GE. Interactive Effects of Age and Hypertension on Volumes of Brain Structures. Stroke. 1997;28:1410–1417. [PubMed]
  • Takeda S, Sato N, Ogihara T, Morishita R. The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer’s disease: new therapeutic potential. Front Biosci. 2008;13:2253–2265. [PubMed]
  • Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme Medical Publishers; New York: 1988.
  • Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61:1667–1672. [PubMed]
  • Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117:3393–3402. [PMC free article] [PubMed]
  • Wiseman RM, Saxby BK, Burton EJ, Barber R, Ford GA, O’Brien JT. Hippocampal atrophy, whole brain volume, and white matter lesions in older hypertensive subjects. Neurology. 2004;63:1892–1897. [PubMed]